6533b873fe1ef96bd12d4f21
RESEARCH PRODUCT
Mitochondrial myopathy--a result of clofibrate/etofibrate treatment? Case report.
Hans-hilmar GoebelA. BardosiP. Scheidtsubject
Malemedicine.medical_specialtySide effectKearns-Sayre SyndromePathology and Forensic Medicine03 medical and health sciencesCellular and Molecular NeuroscienceClofibric Acid0302 clinical medicineMitochondrial myopathyMuscular DiseasesInternal medicinemedicineHumansClofibrateMyopathy030304 developmental biologyAgedHypolipidemic Agents0303 health sciencesMuscle biopsyClofibratemedicine.diagnostic_testbusiness.industryMusclesForme frustemedicine.disease3. Good healthDiscontinuationMitochondria MuscleMicroscopy ElectronEndocrinologyEtofibrateNeurology (clinical)medicine.symptombusiness030217 neurology & neurosurgerymedicine.drugdescription
A 66-year-old man had developed a myopathy while undergoing several periods of etofibrate and clofibrate therapy over the past 5 years. Discontinuation of etofibrate treatment failed to reverse his muscle illness which, however, did not progress. A muscle biopsy revealed a chronic myopathy marked by abundant, abnormally structured muscle mitochondria. His mitochondrial myopathy may represent a forme fruste of the Kearns-Sayre syndrome or other types of mitochondrial myopathy, clinically made evident by the etofibrate/clofibrate therapy, or a permanent, adverse side effect of clofibrate treatment. If the latter assumption proves to be correct, it will indicate that clofibrate therapy may induce an acutely painful but reversible neuromuscular illness, or also, though rarely, a chronic mitochondrial myopathy.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 1985-01-01 | Acta neuropathologica |